Psychiatr. praxi. 2023;24(1):51-55 | DOI: 10.36290/psy.2023.006

Otázky a odpovědi v léčbě schizofrenie

MUDr. Jozef Višňovský
Klinika psychiatrie, FN Olomouc

(Na základě přednášek prof. MUDr. Pavla Mohra, Ph.D., MUDr. Miloslava Kopečka, Ph.D., a prof. MUDr. Jiřího Masopusta, Ph.D.) 
V rámci 65. konference ČNPS v Mariánských Lázních se uskutečnilo sympozium věnované otázkám a odpovědím v léčbě schizofrenie se zaměřením na moderní antipsychotikum kariprazin.

Accepted: March 29, 2023; Published: April 11, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Višňovský J. Otázky a odpovědi v léčbě schizofrenie. Psychiatr. praxi. 2023;24(1):51-55. doi: 10.36290/psy.2023.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Front Psychiatry. 2022;12:781946. doi: 10.3389/fpsyt.2021.781946. PMID: 35145438; PMCID: PMC8821167. Go to original source... Go to PubMed...
    2. Citrome L. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? CNS Spectr. 2016;21(S1):1-12. doi: 10.1017/S1092852916000729. PMID: 28044942. Go to original source... Go to PubMed...
    3. Huhn M, Nikolakopoulou A, Schneider­‑Thoma J, et al. Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi­‑Episode (Schizophrenia: A Systematic Review and Network Meta­‑Analysis. Focus (Am Psychiatr Publ). 2020;184:443-455. doi: 10.1176/appi.focus.18306. Epub 2020. PMID: 33343258; PMCID: PMC7725155. Go to original source... Go to PubMed...
    4. Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double­‑blind, controlled trial. Lancet. 2017; 389(10074):1103-1113. doi: 10.1016/S0140-6736(17)30060-0. Epub 2017. Erratum in: Lancet. 2017; 389(10074):1102. PMID: 28185672. Go to original source... Go to PubMed...
    5. Pappa S, Kalniunas A, Sharma H. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Ther Adv Psychopharmacol. 2022;12:20451253221132087. doi: 10.1177/20451253221132087. PMID: 36439679; PMCID: PMC9685211. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.